PT - JOURNAL ARTICLE AU - Lin Fu AU - Jun Fei AU - Shen Xu AU - Hui-Xian Xiang AU - Ying Xiang AU - Zhu-Xia Tan AU - Meng-Die Li AU - Fang-Fang Liu AU - Ying Li AU - Ming-Feng Han AU - Xiu-Yong Li AU - Hui Zhao AU - De-Xiang Xu TI - Acute liver injury and its association with death risk of patients with COVID-19: a hospital-based prospective case-cohort study AID - 10.1101/2020.04.02.20050997 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.02.20050997 4099 - http://medrxiv.org/content/early/2020/04/06/2020.04.02.20050997.short 4100 - http://medrxiv.org/content/early/2020/04/06/2020.04.02.20050997.full AB - Background Coronavirus disease 2019 (COVID-19) is a newly respiratory infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) with multiple organ injuries. The aim of this study was to analyze SARS-CoV-2-induced acute liver injury (ALI), its association with death risk and prognosis after discharge.Methods Three-hundred and fifty-five COVID-19 patients were recruited. Clinical data were collected from electronic medical records. ALI was evaluated and its prognosis was tracked. The association between ALI and death risk was analyzed.Results Of 355 COVID-19 patients, 211 were common, 88 severe, and 51 critical ill cases, respectively. On admission, 223 (62.8%) patients were with hypoproteinemia, 151(42.5%) with cholestasis, and 101 (28.5%) with hepatocellular injury. As expected, ALI was more common in critical ill patients. By multivariate logistic regression, male, older age and lymphocyte reduction were three important independent risk factors predicting ALI among COVID-19 patients. Death risk analysis shows that fatality rate was higher among patients with hypoproteinemia than those without hypoproteinemia (RR=9.471, P<0.001). Moreover, fatality rate was higher among patients with cholestasis than those without cholestasis (RR=2.182, P<0.05). Follow-up observation found that more than one hepatic functional indexes of two-third patients remained abnormal 14 days after discharge.Conclusions ALI at early stage elevates death risk of COVID-19 patients. SARS-CoV-2-induced ALI has not recovered completely 14 days after discharge.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by National Natural Science Foundation of China (grants number: 81630084) and National Natural Science Foundation Incubation Program of the Second Affiliated Hospital of Anhui Medical University (grant number: 2019GQFY06).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available.